Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A subset of side effects continued to improve over time,” said the study’s senior author, Douglas Johnson, MD, MSCI, clinical director of melanoma at Vanderbilt-Ingram Cancer Center and holder of the Susan and Luke Simons Directorship.